REVIEW ARTICLE

Discovering New Horizons: A Systematic Review on Artificial Intelligence Applications in Drug Discovery and Development

Dillip Kumar Sahoo[1*], Rashmi Ranjan Sarangi[2], Sanjay Kumar Nayak[3] , Rajeshwar V[4], Mohammed Sayeed[4]

[1]*Sahajpath College of Pharmacy, Bira, Balisha More, North 24 Parganas, West Bengal, India.*
[2]*Royal College of Pharmacy and Health Sciences, Berhampur, Odisha, India.*
[3]*College of Pharmaceutical Sciences, Marine Drive Road, Puri, Odisha, India.*
[4]*School of Pharmacy, Anurag University, Venkatapur, Hyderabad, Telangana, India.*

Received: 05th March, 2024; Revised: 26th May, 2024; Accepted: 03rd July, 2024; Available Online: 31st August, 2024

ABSTRACT

The intersection of AI and the pharmaceutical domain represents a fundamental transformation offering novel possibilities to accelerate the drug design and development timeline by enhancing precision in therapeutic modalities. We focused on the amalgamation of these two domains in a strategic view of bringing out the potential and précised drug candidates by overcoming the challenges triggered by traditional formulation methods. Our aim is to thoroughly analyze the diverse applications of AI from its significant contribution to target identification and authentication of its influence on clinical trial optimization.

Functioning as an intellectual guide, this systematic review directs readers through the undiscovered area where the zones of artificial intelligence and pharmaceutical sciences collaborate. By acquiring the required information from various studies and methodologies, our systematic review endeavors not only to present a retrospective analysis of AI's influence but also to provide a forward-thinking perspective on its transformative possibilities.

Keywords: Artificial intelligence, Drug discovery, Machine learning.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.08

How to cite this article: Sahoo DK, Sarangi RR, Nayak SK, Rajeshwar V, Sayeed M. Discovering New Horizons: A Systematic Review on Artificial Intelligence Applications in Drug Discovery and Development. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1151-1157.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

In the dynamic and ever-changing area of pharmaceutical research and development, the interconnection between science and technology has been initiated to groundbreaking advancements. In the midst of these transformative technologies, Artificial Intelligence (AI) has emerged as a potent force, challenging and reshaping the existing norms in drug discovery and development.[1] The pharmaceutical industry, driven by a persistent search for innovative therapeutic solutions, faces both opportunities and challenges in the age of AI. Machine learning algorithms, predictive modeling, and data analytics have revitalized the approach to target identification, lead optimization, and clinical trial design.[2]

AI has significantly improved the drug development process by making it faster, more cost-effective, and increasing success rates. From speeding up drug repurposing to enhancing target validation, AI is expected to play a key role. Exploring various AI applications, such as virtual screening and patient stratification, our goal is to uncover the potential benefits and opportunities these technologies offer.[3]

This systematic review not only consolidates existing literature but also critically evaluates methodologies, challenges, and prospects of AI integration in drug discovery. In doing so, we aspire to contribute valuable insights fostering innovation, collaboration, and the continual advancement of therapeutic solutions for researchers, practitioners, and stakeholders guiding the pivotal convergence of AI and pharmaceutical sciences for the benefit of global healthcare.[4]

Artificial Intelligence Techniques in Drug Discovery (Figure 1)

Artificial Intelligence (AI) techniques have significantly emerged as powerful tools in drug discovery, offering novel approaches to accelerate the identification and optimization of potential therapeutic agents. In this section, we discuss three primary AI techniques employed in drug discovery: Machine

*Author for Correspondence: sahoo4@gmail.com

Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP).[5]

Machine learning (ML)

ML algorithms have been widely utilized in various stages of drug discovery, from target identification to lead optimization. Key applications include:

- *Target identification and validation*

ML models analyze biological data, such as genomics, proteomics, and transcriptomics, to identify disease-associated targets and organize them for further investigation.[6]

- *Predictive modelling for compound activity and toxicity*

ML algorithms capitalize on large datasets of chemical compounds and their biological activities to predict their efficacy and toxicity. These models assist in choosing primary compounds with effective pharmacological characteristics and minimized safety risks.[7]

Deep learning

DL, a subset of ML, has shown remarkable capability in handling complex data modalities that are fundamental in drug discovery, such as molecular structures and biological images.

- *Image-based drug discovery*

DL models examine high-volume of imaging data to detect compounds with desired biological effects, such as phenotypic screening for drug candidates.[8]

- *Protein structure prediction and drug design*

DL algorithms predict protein-ligand interactions and help in rational drug design by constructing novel molecular structures with improved binding affinity and specificity.[9]

Natural language processing

NLP techniques enable the extraction and interpretation of information from vast biomedical literature, facilitating knowledge-driven drug discovery. Key applications include:

- *Text mining for drug repurposing*

NLP algorithms are used to study the scientific literature to find new uses for existing drugs by revealing connections between drugs, targets, and diseases.[10]

- *Automated literature curation*

NLP systems extract necessary information from biomedical texts, such as drug-drug interactions, adverse drug reactions, and pharmacokinetic properties to optimize fact-based decision-making in drug development.[11]

AI Applications in Drug Development

Artificial Intelligence (AI) has significantly impacted various stages of drug development by offering novel solutions to the complex challenges encountered by traditional approaches.[12] Here are the few applications of AI which are expected to make notable contributions to drug development:

Lead optimization

AI algorithms facilitate the refinement of lead compounds by predicting their pharmacological properties and potency, selectivity, safety profiles etc. Through techniques such as virtual screening and de novo drug design, AI accelerates the discovery of potential drug candidates with improved therapeutic efficacy.[13]



Figure 1: Applications of AI in drug discovery

Structure-activity relationship (SAR) analysis

SAR analysis involves investigating how the modifications to the chemical structure of a compound influence its biological activity. Naturally, scientists conduct SAR analysis through experimentation, synthesizing and testing various substitutes to detect the optimal structure with a rational pharmacological profile. As this approach is resource-exhaustive and time-consuming, the collaboration of AI with SAR analysis could be beneficial to researchers in analyzing numerous datasets of structures and corresponding biological activities, which helps in predicting models that can forecast the physiological response of new moieties based on their structural changes.[14]

AI-driven SAR analysis offers several advantages in lead optimization (Figure 2)

Rapid screening

AI algorithms can quickly screen large chemical libraries, selecting compounds with the greatest potential for biological efficacy, which speeds up the discovery of promising drug candidates for enhanced optimization.[15]

Insightful predictions

AI models can uncover delicate structure-activity relationships and non-linear patterns that may not be possible through traditional methods. This facilitates researchers to attain a more profound understanding of the fundamental mechanisms guiding compound behavior and make crucial decisions in the optimization of chemical compounds.[16]

Feedback-driven design

AI facilitates progressive design cycles by providing real-time feedback on the predicted response of newly developed compounds.[17]

Resource efficiency

By minimizing the requirement for exhaustive experimental testing, AI-based SAR analysis safeguards resources and reduces costs associated with drug optimization. This allows researchers to bring forth the most promising candidates, enhancing efficiency and productivity.[18]



Figure 2: Schematic representation of the integration of AI with drug discovery

Virtual screening

Virtual screening involves the computational screening of huge chemical libraries to identify potential drug candidates that are likely to bind to a target such as a protein receptor involved in a disease pathway.[19] The process typically involves the following steps:

- *Target selection*

The first step involves selecting a molecule that targets the disease of interest.[20]

- *Ligand library preparation*

A diverse library of small molecules (ligands) is prepared from databases for screening.[21]

- *Docking and scoring*

Molecular docking algorithms are utilized to predict the binding phenomenon and affinity of ligands to the target receptor. Scoring functions are used to evaluate and rank the binding affinity based on their predicted affinity.[22]

- *Hit identification*

Compounds found with the highest binding affinity are identified as potential hits for further experimental validation.[23]

De novo drug design

It involves the computational generation of novel molecular structures that are predicted to interact with a specified target (Figure 3). This approach is particularly valuable in situations where no appropriate lead compounds are accessible for further optimization.[24,25] It involves the following steps:

- *Target identification and characterization*

The target protein or receptor implicated in the disease pathway is identified and characterized using structural biology and bioinformatics techniques.[26]

- *Molecular design*

Computational algorithms, such as fragment-based design or molecular modeling techniques, are employed to create new molecular scaffolds or ligands that are anticipated to bind to the target with strong affinity.[27]

- *Virtual screening*

The designed molecules are subjected to virtual screening against the target receptor, which facilitates estimating their binding affinity and selectivity.[28]

- *Drug candidate optimization*

Promising lead compounds identified through de novo design are further optimized through repetitive phases of medicinal chemistry, computational modeling, and biological evaluation to enhance their characteristics as drug candidates with ensured therapeutic efficacy.[29]

Pharmacokinetic modelling

Pharmacokinetic modeling, when combined with artificial intelligence, enhances the prediction of ADME properties of potential drug candidates.[30]

- *Absorption*

AI models analyze the physicochemical properties of drug molecules, such as solubility, lipophilicity, and molecular size, to estimate their absorption ratio. Machine learning algorithms derived from datasets of known drug absorption profiles are employed to generate predictive models that quantify the extent and rate of drug absorption *in-vivo*.[31]

- *Distribution*

AI algorithms compute the data of drug physicochemical properties, blood flow rates to various tissues, and protein binding affinity to measure the distribution profile of drugs.[32]

- *Metabolism*

AI-based metabolic modeling integrates information on drug structure, enzyme kinetics, and genetic polymorphisms to measure metabolic pathways and identify potential metabolites.[33]

- *Excretion*

AI models utilize the data on renal function and transporter activity to determine the rate and extent of drug excretion.[34]

Optimization of dosing regimens and formulation design

Utilization of Artificial Intelligence (AI) techniques in optimizing drug candidates and their dosage forms by



Figure 3: A graphical flowchart showing how a pharmacologically active molecule is developed, from its design to sharing the knowledge gained

leveraging computational methods to enhance the efficacy, safety, and patient adherence to drug therapies.[35]

- *Personalized medication protocols*

By incorporating data such as patient demographics, clinical characteristics, genetic information, and biomarkers into AI algorithms, they can facilitate the quantification of optimal dosing regimens customized to individual patient profiles, maximizing therapeutic efficacy while minimizing adverse effects and reducing the risk of under- or over-dosing.[36]

- *Formulation design*

By simulating drug release kinetics, solubility, stability, and bioavailability, AI models guide the choice of formulation ingredients and manufacturing processes to enhance drug efficacy and patient compliance.[37]

- *Real-time monitoring and feedback*

AI-enabled devices and digital health platforms facilitate real-time monitoring of patient responses to therapy, including drug concentrations, physiological parameters, and clinical outcomes.[38]

Drug repurposing

AI in drug repurposing uses advanced computational methods to find new therapeutic applications for existing drugs. This approach can greatly speed up the drug development process and lower costs, since the safety profiles of these drugs are already known. AI contributes to drug repurposing in the following ways.[39]

- *Text mining*

Natural language processing (NLP) algorithms extract probable information from scientific publications and databases to uncover potential drug-disease relationships.

- *Biological network analysis*

AI inspects biological networks, including protein-protein interactions and gene regulatory networks, to understand how existing drugs might influence various pathways and diseases. This method can uncover unexpected connections between drugs and diseases.[40]

- *In silico screening*

AI conducts virtual screenings of drug libraries against various disease targets using computational models. This approach identifies candidate drugs that may have therapeutic effects on new diseases without the need for initial experimental screening.[41]

- *Docking studies*

AI-driven molecular docking studies predict how existing drugs might bind with new target proteins, providing necessary information for potential repurposing.[42]

- *Faster timelines*

As repurposing is done for the drugs that have already been approved, the time required for early-stage development and safety testing can be saved, leading to faster clinical trials and regulatory approvals.[43]

- *Patient stratification*

AI can be used to identify subgroups of patients based on their genetic, phenotypic, or biomarker profiles, which enhances the precision and effectiveness of treatments by the application of repurposed drugs.[44]

Clinical trial optimization

AI in clinical trial optimization utilizes cutting-edge technologies to enhance the efficiency, cost-effectiveness, and success rates of clinical trials[45] shown in Figure 4. Here is a detailed examination of how AI optimizes various stages of clinical trials:

- *Patient recruitment and enrollment*

AI algorithms scan electronic health records (EHRs), genetic data, and patient databases to identify individuals who meet specific trial criteria, thereby expanding the range of eligible individuals and reducing recruitment time.[46]

- *Adaptive trial designs*

AI facilitates the development of adaptive trial designs that can be adjusted based on obtained results, making trials more flexible and efficient and potentially reducing both the time and cost of development.[47]

- *Data quality and integrity*

AI algorithms detect and correct errors, inconsistencies, and missing data, promising high-quality and reliable information for analysis.[48]

- *Predictive analytics*

AI inspects collected data in real-time to identify trends, predict outcomes, and generate insights, informing trial decisions and modifications.[49]



Figure 4: Number of molecules discovered by AI-first Biotechs that have entered clinical trials. The analysis includes molecules that were partnered with pharmaceutical companies and excludes COVID-19-related molecules. (a) AI-discovered molecules by clinical Phase. (b) AI-discovered molecules by mode-of-discovery.

- *Remote monitoring*

AI enables remote monitoring of patients through wearable devices and mobile applications, reducing the need for recurrent in-person visits by improving patient compliance.[50]

- *Adverse event prediction*

AI models predict the occurrence of adverse events based on patient data, allowing for early detection and enhancing patient safety.[51]

- *Automated reporting*

AI automates the creation of regulatory reports, ensuring timely and accurate submissions to regulatory authorities.[52]

CONCLUSION

The systematic review on applications of artificial intelligence (AI) in drug discovery and development focuses on the transformative potential of AI in revolutionizing the pharmaceutical industry. AI-enabled methodologies offer significant advantages over traditional approaches, including enhanced efficiency, cost reduction, and improved accuracy in various stages of drug development.

From detecting promising drug molecules through virtual screening and de novo drug design to optimizing lead compounds and repurposing existing drugs, AI's optimistic power complements human expertise and speeds up the drug discovery pipeline. Additionally, AI's capability to integrate and analyze huge datasets, identify pharmacokinetic properties, and optimize clinical trial processes by further enhances the overall effectiveness and success rates of drug development procedures.

Despite these applications, it is essential to remember that AI cannot entirely replace human expertise. The collaboration between AI technologies and the knowledge of researchers is crucial for making appropriate decisions and ensuring the reliability of outcomes. As AI continues to blossom, ongoing collaboration between AI experts and pharmaceutical researchers will play a prominent role in unlocking its maximum potential.

In conclusion, the amalgamation of AI with drug discovery and development represents an innovative edge that can lead to faster, more efficient, and cost-effective solutions for addressing medical needs that were unmet. By embracing AI-driven innovations, the pharmaceutical industry can achieve new horizons in delivering therapeutic advancements and improving patient care.

REFERENCES

1. Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Advanced drug delivery reviews. 2020 Jan 1;158:4-16.
2. Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine learning methods in drug discovery. Molecules. 2020 Nov 12;25(22):5277.
3. Fitzgerald J, Higgins D, Vargas CM, Watson W, Mooney C, Rahman A, Aspell N, Connolly A, Gonzalez CA, Gallagher W. Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. Journal of Clinical Pathology. 2021 Jul 1;74(7):429-34.
4. Jones CH, Madhavan S, Natarajan K, Corbo M, True J, Dolsten M. Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world. Drug Discovery Today. 2024 Jul 23:104112.
5. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021 Aug;25:1315-60.
6. Dar MA, Arafah A, Bhat KA, Khan A, Khan MS, Ali A, Ahmad SM, Rashid SM, Rehman MU. Multiomics technologies: role in disease biomarker discoveries and therapeutics. Briefings in Functional Genomics. 2023 Mar;22(2):76-96.
7. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023 Jun 18;16(6):891.
8. Sinha K, Ghosh N, Sil PC. A review on the recent applications of deep learning in predictive drug toxicological studies. Chemical Research in Toxicology. 2023 Aug 10;36(8):1174-205.
9. Dhakal A, McKay C, Tanner JJ, Cheng J. Artificial intelligence in the prediction of protein–ligand interactions: recent advances and future directions. Briefings in Bioinformatics. 2022 Jan;23(1):bbab476.
10. Khan JY, Khondaker MT, Hoque IT, Al-Absi HR, Rahman MS, Guler R, Alam T, Rahman MS. Toward preparing a knowledge base to explore potential drugs and biomedical entities related to COVID-19: automated computational approach. JMIR medical informatics. 2020 Nov 10;8(11):e21648.
11. Romano JD, Tatonetti NP. Informatics and computational methods in natural product drug discovery: a review and perspectives. Frontiers in Genetics. 2019 Apr 30;10:368.
12. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019 Mar 1;24(3):773-80.
13. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. 2023 Sep 28:1-38.
14. Kenny SE, Antaw F, Locke WJ, Howard CB, Korbie D, Trau M. Next-Generation Molecular Discovery: From Bottom-Up In Vivo and In Vitro Approaches to In Silico Top-Down Approaches for Therapeutics Neogenesis. Life. 2022 Mar 2;12(3):363.
15. Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R, Kulkarni RV, Raghu AV. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antiviral Research. 2023 Nov 5:105740.
16. Ahmadi M, Shahlaei M. Quantitative structure–activity relationship study of P2X7 receptor inhibitors using combination of principal component analysis and artificial intelligence methods. Research in Pharmaceutical Sciences. 2015 Jul 1;10(4):307-25.
17. Zhou C, Zhang X, Yu C. How does AI promote design iteration? The optimal time to integrate AI into the design process. Journal of Engineering Design. 2023 Dec 27:1-28.
18. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. Drug Development Research. 2023 Dec;84(8):1652-

63.
19. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN. Virtual screening in drug discovery-a computational perspective. Current Protein and Peptide Science. 2007 Aug 1;8(4):329-51.
20. Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML. Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases. Current Topics in Medicinal Chemistry. 2019 Jul 1;19(19):1694-711.
21. Fradera X, Babaoglu K. Overview of methods and strategies for conducting virtual small molecule screening. Current protocols in chemical biology. 2017 Jan;9(3):196-212.
22. Naqvi AA, Mohammad T, Hasan GM, Hassan MI. Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Current Topics in Medicinal Chemistry. 2018 Aug 1;18(20):1755-68.
23. Laggner C, Schieferer C, Fiechtner B, Poles G, Hoffmann RD, Glossmann H, Langer T, Moebius FF. Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. Journal of Medicinal Chemistry. 2005 Jul 28;48(15):4754-64.
24. Zhu T, Cao S, Su PC, Patel R, Shah D, Chokshi HB, Szukala R, Johnson ME, Hevener KE. Hit identification and optimization in virtual screening: Practical recommendations based on a critical literature analysis: Miniperspective. Journal of Medicinal Chemistry. 2013 Sep 12;56(17):6560-72.
25. Mouchlis VD, Afantitis A, Serra A, Fratello M, Papadiamantis AG, Aidinis V, Lynch I, Greco D, Melagraki G. Advances in de novo drug design: from conventional to machine learning methods. International Journal of Molecular Sciences. 2021 Feb 7;22(4):1676.
26. Al-Mustanjid M, Mahmud SH, Royel MR, Rahman MH, Islam T, Rahman MR, Moni MA. Detection of molecular signatures and pathways shared in inflammatory bowel disease and colorectal cancer: a bioinformatics and systems biology approach. Genomics. 2020 Sep 1;112(5):3416-26.
27. Sheng C, Zhang W. Fragment informatics and computational fragment-based drug design: an overview and update. Medicinal Research Reviews. 2013 May;33(3):554-98.
28. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery. 2004 Nov;3(11):935-49.
29. Domenico A, Nicola G, Daniela T, Fulvio C, Nicola A, Orazio N. De novo drug design of targeted chemical libraries based on artificial intelligence and pair-based multiobjective optimization. Journal of Chemical Information and Modeling. 2020 Aug 26;60(10):4582-93.
30. Tran TT, Tayara H, Chong KT. Recent studies of artificial intelligence on in silico drug distribution prediction. International Journal of Molecular Sciences. 2023 Jan 17;24(3):1815.
31. Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opinion on Drug Metabolism & Toxicology. 2005 Jun 1;1(1):159-68.
32. Kumar R, Sharma A, Siddiqui MH, Tiwari RK. Prediction of drug-plasma protein binding using artificial intelligence-based algorithms. Combinatorial Chemistry & high throughput screening. 2018 Jan 1;21(1):57-64.
33. Pawar V, Patil A, Tamboli F, Gaikwad D, Mali D, Shinde A. Harnessing the power of AI in pharmacokinetics and pharmacodynamics: A comprehensive review. AAPS PharmSciTech. 2021;14(2):426-39.
34. Miners JO, Yang X, Knights KM, Zhang L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clinical Pharmacology & Therapeutics. 2017 Sep;102(3):436-49.
35. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1916.
36. Kalinin AA, Higgins GA, Reamaroon N, Soroushmehr S, Allyn-Feuer A, Dinov ID, Najarian K, Athey BD. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics. 2018 May 1;19(7):629-50.
37. Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Advanced Drug Delivery Reviews. 2021 Aug 1;175:113806.
38. Shajari S, Kuruvinashetti K, Komeili A, Sundararaj U. The emergence of AI-based wearable sensors for digital health technology: a review. Sensors. 2023 Nov 29;23(23):9498.
39. Pan X, Lin X, Cao D, Zeng X, Yu PS, He L, Nussinov R, Cheng F. Deep learning for drug repurposing: Methods, databases, and applications. Wiley Interdisciplinary Reviews: Computational Molecular Science. 2022 Jul;12(4):e1597.
40. Olivetti EA, Cole JM, Kim E, Kononova O, Ceder G, Han TY, Hiszpanski AM. Data-driven materials research enabled by natural language processing and information extraction. Applied Physics Reviews. 2020 Dec 1;7(4).
41. Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, Sahana R, Kulkarni RV, Raghu AV. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antiviral Research. 2023 Nov 5:105740.
42. Dhakal A, McKay C, Tanner JJ, Cheng J. Artificial intelligence in the prediction of protein–ligand interactions: recent advances and future directions. Briefings in Bioinformatics. 2022 Jan;23(1):bbab476.
43. Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC health services research. 2022 Jul 29;22(1):970.
44. Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Frontiers in Pharmacology. 2020 Aug 12;11:1177.
45. Sehrawat SK. Transforming Clinical Trials: Harnessing the Power of Generative AI for Innovation and Efficiency. Transactions on Recent Developments in Health Sectors. 2023 Sep 14;6(6):1-20.
46. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019 Aug 1;40(8):577-91.
47. Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, Hsu CH, König F, Krams M, Liu Q, Neuenschwander B, Parke T. Innovative approaches for designing and analyzing adaptive dose-ranging trials. Journal of biopharmaceutical statistics. 2007 Nov 8;17(6):965-95.
48. Aldoseri A, Al-Khalifa KN, Hamouda AM. Re-thinking data strategy and integration for artificial intelligence: concepts, opportunities, and challenges. Applied Sciences. 2023 Jun 13;13(12):7082.
49. Yin J, Ngiam KY, Teo HH. Role of artificial intelligence

applications in real-life clinical practice: systematic review. Journal of medical Internet research. 2021 Apr 22;23(4):e25759.
50. Barnes R, Zvarikova K. Artificial intelligence-enabled wearable medical devices, clinical and diagnostic decision support systems, and Internet of Things-based healthcare applications in COVID-19 prevention, screening, and treatment. American Journal of Medical Research. 2021;8(2):9-22.
51. Sevakula RK, Au-Yeung WT, Singh JP, Heist EK, Isselbacher EM, Armoundas AA. State-of-the-art machine learning techniques aiming to improve patient outcomes pertaining to the cardiovascular system. Journal of the American Heart Association. 2020 Feb 18;9(4):e013924.
52. Singh C, Yashwant, Gupta AK. Formulation and the Study of Finished Products Used for Anginal Disease. International Journal of Pharmaceutical Quality Assurance. 2022;13(4):385-388. DOI: 10.25258/ijpqa.13.4.07